Tislelizumab With Chemotherapy and Thoracic Radiotherapy for Extensive-stage Small-Cell Lung Cancer A Phase II Multicenter Study

What this Trial Is About

Researchers are evaluating the preliminary effectiveness and safety of Tislelizumab combined with thoracic radiotherapy and chemotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer. This is a phase II, single-arm, open, multicenter study aiming to explore this combination therapy in people newly diagnosed with this condition. Participants will receive Tislelizumab infusions 200 mg every 3 weeks for up to 2 years. They will also receive chemotherapy with Etoposide plus either Carboplatin or Cisplatin for 4 cycles every 3 weeks. Concurrent thoracic radiotherapy will be given using intensity-modulated radiation therapy IMRT with doses between 30 to 45 Gy over 10 to 15 fractions. Throughout the study, participants will be closely monitored with imaging to assess tumor response and disease progression for up to 2 years. Researchers will track progression-free survival as the main outcome, along with response rates, overall survival, and any side effects. Participants will have regular visits for assessments and follow-ups to monitor treatment effects and safety during and after therapy.

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC